These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 16624725

  • 1. The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation.
    Impellizeri JA, Howell K, McKeever KP, Crow SE.
    Vet J; 2006 May; 171(3):556-8. PubMed ID: 16624725
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R, Hagenbeek A.
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [Abstract] [Full Text] [Related]

  • 4. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
    Tobinai K.
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
    [Abstract] [Full Text] [Related]

  • 5. [Rituximab in the treatment of B-cell non-Hodgkin lymphoma].
    Mitrović Z, Aurer I.
    Lijec Vjesn; 2006 Mar; 128(1-2):36-42. PubMed ID: 16640226
    [Abstract] [Full Text] [Related]

  • 6. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Rituximab for the treatment of diffuse large B-cell lymphomas.
    Held G, Pöschel V, Pfreundschuh M.
    Expert Rev Anticancer Ther; 2006 Aug 01; 6(8):1175-86. PubMed ID: 16925484
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.
    Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S.
    Leuk Res; 2006 May 01; 30(5):625-31. PubMed ID: 16289746
    [Abstract] [Full Text] [Related]

  • 13. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
    Ansell SM, Geyer SM, Maurer MJ, Kurtin PJ, Micallef IN, Stella P, Etzell P, Novak AJ, Erlichman C, Witzig TE.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6056-63. PubMed ID: 17062681
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial.
    Witzens-Harig M, Reiz M, Heiss C, Benner A, Hensel M, Neben K, Dreger P, Kraemer A, Ho AD.
    Ann Hematol; 2009 Jan 15; 88(1):51-7. PubMed ID: 18665360
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
    Ratanatharathorn V, Pavletic S, Uberti JP.
    Cancer Treat Rev; 2009 Dec 15; 35(8):653-61. PubMed ID: 19682801
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
    Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Mishima Y, Kuniyoshi R, Taniyama A, Yokoyama M, Sakajiri S, Takeuchi K, Watanabe C, Takahashi S, Ito Y, Hatake K.
    Clin Cancer Res; 2009 Apr 01; 15(7):2523-30. PubMed ID: 19276251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.